title: Use of Bacille Calmette-Guèrin (BCG) in multiple sclerosis.
abstract: We studied the effect of Bacille Calmette-Guerin (BCG) vaccine as an immunomodulator in MS. According to the guidelines for clinical trials in MS, a single crossover, MRI-monitored trial was performed in 14 patients with relapsing-remitting MS. After treatment, MRI activity was significantly reduced. No major adverse effects were reported. Adjuvant therapy with BCG vaccine was safe and merits study in MS.
authors.affiliation: Department of Neurological Sciences, Università La Sapienza, Rome, Italy.
authors.forename: G
authors.initials: G
authors.lastname: Ristori
authors.forename: M G
authors.initials: MG
authors.lastname: Buzzi
authors.forename: U
authors.initials: U
authors.lastname: Sabatini
authors.forename: E
authors.initials: E
authors.lastname: Giugni
authors.forename: S
authors.initials: S
authors.lastname: Bastianello
authors.forename: F
authors.initials: F
authors.lastname: Viselli
authors.forename: C
authors.initials: C
authors.lastname: Buttinelli
authors.forename: S
authors.initials: S
authors.lastname: Ruggieri
authors.forename: C
authors.initials: C
authors.lastname: Colonnese
authors.forename: C
authors.initials: C
authors.lastname: Pozzilli
authors.forename: M
authors.initials: M
authors.lastname: Salvetti
mesh_terms: D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000328:Adult; D001500:BCG Vaccine / Q000627:therapeutic use*; D001921:Brain / Q000473:pathology; D018592:Cross-Over Studies; D005260:Female; D006801:Humans; D008279:Magnetic Resonance Imaging; D008297:Male; D009103:Multiple Sclerosis / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D012008:Recurrence; D016896:Treatment Outcome
chemical_list: D000276:Adjuvants, Immunologic; D001500:BCG Vaccine